Problem

Persist AI addresses the formulation bottleneck in pharmaceutical development: converting a promising molecule into a stable, scalable, manufacturable drug product. Sustained-release formulation work can take roughly three to five years and cost $10 million or more, because scientists rely on repetitive trial and error and because a formulation that works in a small laboratory batch may fail during commercial scale-up, causing costly delays and redevelopment.

Its clearest use case is complex long-acting injectables, where a single injection may need to release medicine over weeks, months, or even up to a year. These formulations are technically difficult to optimize, particularly for biologics, yet they can improve adherence and outcomes for chronic-disease patients while helping pharmaceutical companies reach the market and revenue sooner.

Product / Service

Persist AI combines machine-learning models, custom robotics, microfluidics, analytical instruments, and high-throughput experimentation in an integrated formulation platform. The AI proposes candidate formulations and next experiments, the robotic laboratory executes them, and the resulting data feeds back into the models in a closed loop until the desired quality target is reached. Its robotics are designed for the organic solvents and complex materials used in pharmaceutical formulation, rather than only the aqueous samples common in biological lab automation.

The company offers two delivery models. Pharmaceutical partners can access the robotic facility through a cloud portal, designing experiments and receiving results and model outputs online, or they can engage Persist for fee-for-service formulation development in which Persist designs, executes, and optimizes the program. The benefit is faster, more reproducible, and more material-efficient formulation discovery: Persist says its platform can produce more than 1,000 formulations monthly, while its published case studies report results such as sustained release in two weeks and a 14-day peptide half-life extension in three months.

Market

Persist AI competes in AI-enabled pharmaceutical formulation development, an emerging intersection of drug-delivery science, laboratory automation, autonomous or “cloud lab” infrastructure, and machine learning. Comparable offerings include Intrepid Labs’ VALIANT platform, which also combines AI and robotics to accelerate formulation optimization, and Atinary’s code-free formulation platform, which designs experiments and integrates with laboratory robots and other automated workflows. Persist’s differentiation is its focus on pharmaceutical formulation, complex materials, miniaturized experiments, and the path from formulation discovery toward scale-up and cGMP manufacturing, especially for long-acting injectables.

The company shows early commercial and ecosystem traction rather than looking like a purely pre-product startup. Founded in 2022, it raised a $4 million seed round and an oversubscribed $12 million Series A, launched its Cloud Lab, reported results from real customer projects, and collaborated with Nivagen on an AI-driven long-acting-injectable manufacturing process. It has also announced 2026 collaborations around low-sample solubility measurement and oral peptide and protein manufacturing. Public evidence reviewed here does not establish revenue or customer-count scale, but Persist says its Series A is supporting a cGMP-compatible line to fulfill customer contracts, which supports an early commercialization-stage characterization.